Abstract 926P
Background
Immunotherapy has significantly improved survival in patients with several solid tumours including head and neck squamous cell carcinoma (HNSCC). Pembrolizumab received approval in the UK in 2020 as first-line treatment for recurrent or metastatic (R/M) HNSCC based on KEYNOTE-048 trial data which demonstrated an extended overall survival (OS) when compared to the EXTREME chemotherapy regime in patients with R/M HNSCC tumours with a combined positive score (CPS)≥1 (Burtness, 2019). Here we, provide real-world data on the clinical outcomes of the use of pembrolizumab as first-line systemic treatment for HNSCC in the United Kingdom (UK).
Methods
Retrospective data analysis of patients with HNSCC treated with pembrolizumab as first-line treatment across 18 centres in UK from 20/03/20 to 31/05/2021.
Results
211 patients were included; the median age was 66.0 (range=39-88.1), 73.0% of patients were male and >65% of patients had a smoking history or alcohol history. In addition to patients with R/M HNSCC, 47 patients had locally advanced disease deemed not suitable for curative treatment at diagnosis; a group of patients not included in KEYNOTE-048. Analysis showed an overall response rate (ORR) of 24.7%, median progression free survival (PFS) of 4.8 months (95% confidence interval [CI]: 3.6-6.1) and median OS of 10.8 months (95% CI 9.0-12.5). 53 patients proceeded to second line treatment and the median PFS2 was 10.2 months (95% CI: 8.8-11.5), similar to PFS2 of 10.3 months for those with CPS≥1 in KEYNOTE-048. The treatment was well-tolerated and only 18 patients (8.5%) stopped pembrolizumab due to an immune-related toxicity (IRT). Moreover, patients with a documented IRT had a statistically significant longer median PFS (11.3 vs 3.3 months; log-rank p-value=<0.001) and median OS (18.8 vs 8.9 months; log-rank p-value <0.001) compared to the groups of patients with no documented IRT.
Conclusions
In this real-world retrospective cohort, we have shown a similar ORR, longer PFS, similar PFS2 and a shorter OS compared to the results of KEYNOTE-48. Those with locally advanced disease deemed not suitable for curative treatment at diagnosis had similar ORR, PFS and OS compared to patients with recurrent or metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Haridass: Non-Financial Interests, Personal, Invited Speaker: MSD. P. Jankowska: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, BMS, AstraZeneca. R. Moleron: Non-Financial Interests, Advisory Board: MSD, Vasodynamics. A. Kong: Non-Financial Interests, Personal, Advisory Board: MSD; Non-Financial Interests, Institutional, Research Funding: AstraZeneca, PUMA; Non-Financial Interests, Personal, Invited Speaker: Merck, BMS; Non-Financial Interests, Personal, Advisory Role: Avinnity. All other authors have declared no conflicts of interest.
Resources from the same session
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12
900P - COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Presenter: Amanda Psyrri
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
907P - Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Presenter: Laura Locati
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12